PDCD1 and hepatocellular carcinoma: Currently, the combination of two or three ICIs with different mechanisms of action (anti-PD-1 antibodies/anti-PD-L1 antibodies/anti-CTLA-4 antibodies) or the combination of a molecular-targeted drug with any ICI is the mainstream treatment for advanced HCC.